XTAE
ARAN
Market cap67mUSD
Jul 22, Last price
4,557.00ILS
1D
4.78%
1Q
17.06%
Jan 2017
74.80%
IPO
1,603.55%
Name
Aran Research and Development 1982 Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aran Research & Development (1982) Ltd., an Israeli company founded in Caesarea in 1982, specializes in the design, development, and manufacturing of various products and equipment, with a significant focus on the plastics industry within Israel. The company boasts a broad portfolio, encompassing a wide array of medical devices such as cardiovascular solutions, in-vitro diagnostic tools, surgical instruments, and advanced imaging and monitoring systems. They are also prominent in fluid management, producing water devices like pressure and flow regulators, a variety of valves (electric, hydraulic, air release, check), sprinklers, drippers, taps, water meters, filters, electronic controllers, and specialized testing equipment. Beyond these core areas, Aran provides portable and stationary control systems for unmanned platforms, electro-optical technologies, and robust electronic hardware engineered for demanding ground, marine, and aerial environments. Their offerings extend to ground systems for security and access control, test and measurement equipment, and production line facilities. The company further manufactures specialized printers, automatic beverage dispensers, sophisticated retail technology like computerized shopping carts and self-checkout kiosks, industrial and communication devices, and batteries. Additionally, Aran acts as a supplier for crucial machinery and components, including injection molding machines, robotics and automation systems, injection molds, hot runner systems, drying, dosing, and conveying systems, plasticizing screws and barrels, and ultrasonic welding and cleaning equipment, along with raw materials. The firm also delivers comprehensive support services and makes strategic investments in emerging medical technology startups.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||